Conversely, inhibition of HAT activity prevents NAFLD: the novel HAT inhibitor, tannic acid, binds to p300 and disrupts its occupancy on lipogenic genes (e.g., Fasn, Acly), leading to hypoacetylation of H3K9ac and H3K36ac (Chung et al., 2019). Here, EP300 is linked to metabolic dysfunction-associated steatotic liver disease.